Cyclopenthiazide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cyclopenthiazide
Accession Number
DB13532
Type
Small Molecule
Groups
Experimental
Description

Cyclopenthiazide is a thiazide diuretic with antihypertensive properties. In a double blind, randomized crossover study, cyclopenthiazide was effective in reducing diastolic blood pressure in mildly hypertensive non-insulin dependent diabetic patients [2]. It is a positive allosteric modulator at AMPA-A receptors [3].

Structure
Thumb
Synonyms
Not Available
Categories
UNII
VX4S2N85F5
CAS number
742-20-1
Weight
Average: 379.87
Monoisotopic: 379.0427261
Chemical Formula
C13H18ClN3O4S2
InChI Key
BKYKPTRYDKTTJY-UHFFFAOYSA-N
InChI
InChI=1S/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)
IUPAC Name
6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=CC2=C(NC(CC3CCCC3)NS2(=O)=O)C=C1Cl

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Cyclopenthiazide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Cyclopenthiazide.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Cyclopenthiazide.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Cyclopenthiazide.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cyclopenthiazide.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Cyclopenthiazide.Approved
AceclofenacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Aceclofenac.Approved
AcemetacinThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Acemetacin.Experimental
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Cyclopenthiazide.Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Cyclopenthiazide.Experimental
AlaproclateAlaproclate may increase the hyponatremic activities of Cyclopenthiazide.Experimental
AlclofenacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Cyclopenthiazide.Approved
AlcuroniumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Alcuronium.Experimental
AldosteroneAldosterone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cyclopenthiazide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Cyclopenthiazide.Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Cyclopenthiazide.Approved
AlminoprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Cyclopenthiazide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Cyclopenthiazide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Cyclopenthiazide.Illicit
AlprenololAlprenolol may increase the hypotensive activities of Cyclopenthiazide.Approved, Withdrawn
AmbrisentanCyclopenthiazide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Cyclopenthiazide.Approved
AmifostineCyclopenthiazide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Cyclopenthiazide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Cyclopenthiazide.Approved, Illicit
AndrographolideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Cyclopenthiazide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Cyclopenthiazide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Cyclopenthiazide.Investigational
AnisodamineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Apocynin.Investigational
ApremilastThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Cyclopenthiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Cyclopenthiazide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Cyclopenthiazide.Investigational
AtenololAtenolol may increase the hypotensive activities of Cyclopenthiazide.Approved
AtracuriumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Atracurium.Experimental
Atracurium besylateThe serum concentration of Cyclopenthiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Azelastine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Cyclopenthiazide.Investigational
BalsalazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Cyclopenthiazide.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Cyclopenthiazide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Cyclopenthiazide.Illicit
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Cyclopenthiazide.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Cyclopenthiazide.Investigational
BenactyzineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilBenazepril may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
BendazacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Cyclopenthiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
BenorilateThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Benzatropine.Approved
BepridilBepridil may increase the hypotensive activities of Cyclopenthiazide.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Cyclopenthiazide.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Cyclopenthiazide.Approved
BethanidineBethanidine may increase the hypotensive activities of Cyclopenthiazide.Approved
BevoniumThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Cyclopenthiazide.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Cyclopenthiazide.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
BiperidenThe serum concentration of Cyclopenthiazide can be increased when it is combined with Biperiden.Approved
BisoprololBisoprolol may increase the hypotensive activities of Cyclopenthiazide.Approved
BornaprineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Bornaprine.Experimental
BosentanBosentan may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Cyclopenthiazide.Investigational
BretyliumBretylium may increase the hypotensive activities of Cyclopenthiazide.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Cyclopenthiazide.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Cyclopenthiazide.Experimental
BromfenacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Cyclopenthiazide.Approved
BufexamacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Bufexamac.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Cyclopenthiazide.Withdrawn
BumadizoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Bumadizone.Experimental
BupranololBupranolol may increase the hypotensive activities of Cyclopenthiazide.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclopenthiazide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclopenthiazide.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CafedrineCafedrine may increase the hypotensive activities of Cyclopenthiazide.Investigational
CalcidiolCyclopenthiazide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolCyclopenthiazide may increase the hypercalcemic activities of Calcipotriol.Approved
CalciumCyclopenthiazide may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetateCyclopenthiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium CarbonateCyclopenthiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Calcium CitrateCyclopenthiazide may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionateCyclopenthiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateCyclopenthiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateCyclopenthiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactateCyclopenthiazide may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Experimental, Vet Approved
Calcium lactate gluconateCyclopenthiazide may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium laevulateCyclopenthiazide may decrease the excretion rate of Calcium laevulate which could result in a higher serum level.Experimental
Calcium pangamateCyclopenthiazide may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphateCyclopenthiazide may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cyclopenthiazide.Approved
CandesartanCandesartan may increase the hypotensive activities of Cyclopenthiazide.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Cyclopenthiazide.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Cyclopenthiazide.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Carbaspirin calcium.Experimental
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Cyclopenthiazide.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Cyclopenthiazide.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
CarprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Cyclopenthiazide.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
CaseinCyclopenthiazide may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CastanospermineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Cyclopenthiazide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Cyclopenthiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Cyclopenthiazide.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Cyclopenthiazide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Cyclopenthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Cyclopenthiazide.Approved, Investigational
CicletanineCicletanine may increase the hypotensive activities of Cyclopenthiazide.Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Cyclopenthiazide.Experimental
CilazaprilCilazapril may increase the hypotensive activities of Cyclopenthiazide.Approved
CitalopramCitalopram may increase the hyponatremic activities of Cyclopenthiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Cyclopenthiazide.Approved, Vet Approved
ClobetasolClobetasol may increase the hypokalemic activities of Cyclopenthiazide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Cyclopenthiazide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Cyclopenthiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Cyclopenthiazide.Approved
ClonidineClonidine may increase the hypotensive activities of Cyclopenthiazide.Approved
ClonixinThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Clonixin.Approved
CloranololCloranolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclopenthiazide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Cyclopenthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Cyclopenthiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Cyclopenthiazide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Cyclopenthiazide.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Cyclopenthiazide.Approved
CurcuminThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Curcumin.Investigational
CyclopentolateThe serum concentration of Cyclopenthiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Cyclophosphamide.Approved, Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Cyclopenthiazide.Approved
CymarinThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Cymarin.Experimental
D-LimoneneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with D-Limonene.Investigational
DapoxetineDapoxetine may increase the hyponatremic activities of Cyclopenthiazide.Investigational
DarifenacinThe serum concentration of Cyclopenthiazide can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Cyclopenthiazide.Approved
DelaprilDelapril may increase the hypotensive activities of Cyclopenthiazide.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Cyclopenthiazide.Investigational
DeserpidineCyclopenthiazide may increase the hypotensive activities of Deserpidine.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Cyclopenthiazide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Cyclopenthiazide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Cyclopenthiazide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Cyclopenthiazide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Cyclopenthiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Cyclopenthiazide.Vet Approved
DexetimideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Cyclopenthiazide.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cyclopenthiazide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyclopenthiazide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Cyclopenthiazide.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DicyclomineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Dicyclomine.Approved
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Cyclopenthiazide.Investigational
DifenpiramideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Cyclopenthiazide.Approved
DiflunisalThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Cyclopenthiazide.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Cyclopenthiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Digoxin.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Cyclopenthiazide.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyclopenthiazide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cyclopenthiazide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyclopenthiazide.Experimental, Illicit
DihydrotachysterolCyclopenthiazide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Cyclopenthiazide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyclopenthiazide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Cyclopenthiazide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Cyclopenthiazide.Approved
DofetilideCyclopenthiazide may increase the QTc-prolonging activities of Dofetilide.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Cyclopenthiazide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Cyclopenthiazide.Approved
DoxercalciferolCyclopenthiazide may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Cyclopenthiazide.Investigational
DroxicamThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Cyclopenthiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Cyclopenthiazide.Approved
DuloxetineDuloxetine may increase the hyponatremic activities of Cyclopenthiazide.Approved
DuvelisibThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with E-6201.Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Cyclopenthiazide.Approved
EmeproniumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Cyclopenthiazide.Approved
EnalaprilEnalapril may increase the hypotensive activities of Cyclopenthiazide.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Cyclopenthiazide.Approved
EndralazineEndralazine may increase the hypotensive activities of Cyclopenthiazide.Experimental
EpanololCyclopenthiazide may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the hypokalemic activities of Cyclopenthiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Cyclopenthiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Epirizole.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Cyclopenthiazide.Approved
EprosartanEprosartan may increase the hypotensive activities of Cyclopenthiazide.Approved
EquileninEquilenin may increase the hypokalemic activities of Cyclopenthiazide.Experimental
EquilinEquilin may increase the hypokalemic activities of Cyclopenthiazide.Approved
ErgocalciferolCyclopenthiazide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Cyclopenthiazide.Approved, Investigational
EstroneEstrone may increase the hypokalemic activities of Cyclopenthiazide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Cyclopenthiazide.Approved
EtanautineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Etanautine.Experimental
EtanerceptThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Cyclopenthiazide.Approved
EthenzamideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cyclopenthiazide.Approved, Illicit
EtodolacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Cyclopenthiazide.Approved
EtoricoxibThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Cyclopenthiazide.Illicit, Vet Approved
EtybenzatropineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Etybenzatropine.Experimental
Evening primrose oilThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
exisulindThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Felbinac.Experimental
FelodipineFelodipine may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
FenbufenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Cyclopenthiazide.Approved
FenoprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Cyclopenthiazide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclopenthiazide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ferulic acid.Experimental
FesoterodineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Fesoterodine.Approved
FloctafenineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Cyclopenthiazide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Cyclopenthiazide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Cyclopenthiazide.Approved, Vet Approved
FlunixinThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Cyclopenthiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Cyclopenthiazide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Cyclopenthiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Cyclopenthiazide.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Cyclopenthiazide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Cyclopenthiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Cyclopenthiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Cyclopenthiazide.Approved
FlurbiprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluvoxamineFluvoxamine may increase the hyponatremic activities of Cyclopenthiazide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Cyclopenthiazide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Cyclopenthiazide.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Cyclopenthiazide.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Cyclopenthiazide.Approved, Vet Approved
GallamineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Gallamine Triethiodide.Approved
GitoformateThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Cyclopenthiazide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Cyclopenthiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Cyclopenthiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Cyclopenthiazide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Cyclopenthiazide.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclopenthiazide.Approved
GlycopyrroniumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Cyclopenthiazide.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Cyclopenthiazide.Approved
GuanazodineCyclopenthiazide may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Cyclopenthiazide.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
GuanoclorCyclopenthiazide may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzCyclopenthiazide may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanCyclopenthiazide may increase the hypotensive activities of Guanoxan.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Cyclopenthiazide.Investigational
HarmalineHarmaline may increase the hypotensive activities of Cyclopenthiazide.Experimental
HE3286HE3286 may increase the hypokalemic activities of Cyclopenthiazide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Cyclopenthiazide.Approved, Illicit
HexamethoniumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Cyclopenthiazide.Approved
HigenamineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Higenamine.Investigational
HomatropineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Cyclopenthiazide.Experimental
HydralazineHydralazine may increase the hypotensive activities of Cyclopenthiazide.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Cyclopenthiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cyclopenthiazide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Cyclopenthiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Cyclopenthiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclopenthiazide.Approved, Illicit
HyoscyamineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Cyclopenthiazide.Investigational
Imidazole salicylateThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Imidazole salicylate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Cyclopenthiazide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Cyclopenthiazide.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Cyclopenthiazide.Approved
IndenololIndenolol may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
IndobufenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Cyclopenthiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Cyclopenthiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Cyclopenthiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Cyclopenthiazide.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Cyclopenthiazide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Cyclopenthiazide.Approved
Ipratropium bromideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Cyclopenthiazide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Cyclopenthiazide.Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Cyclopenthiazide.Approved
IsoxicamThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Cyclopenthiazide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Cyclopenthiazide.Investigational
IvabradineCyclopenthiazide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Cyclopenthiazide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cyclopenthiazide.Approved
KetoprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Cyclopenthiazide.Approved
LacidipineLacidipine may increase the hypotensive activities of Cyclopenthiazide.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
LeflunomideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyclopenthiazide.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Cyclopenthiazide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclopenthiazide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Cyclopenthiazide.Approved
LicoriceLicorice may increase the hypokalemic activities of Cyclopenthiazide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Cyclopenthiazide.Approved
LinsidomineLinsidomine may increase the hypotensive activities of Cyclopenthiazide.Experimental
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Cyclopenthiazide.Approved
LisinoprilLisinopril may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Lisofylline.Investigational
LithiumCyclopenthiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Cyclopenthiazide.Illicit
LofexidineLofexidine may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
LonazolacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Lornoxicam.Approved
LosartanLosartan may increase the hypotensive activities of Cyclopenthiazide.Approved
LoxoprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanCyclopenthiazide may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineManidipine may increase the hypotensive activities of Cyclopenthiazide.Approved
MasoprocolThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Masoprocol.Approved
MazaticolThe serum concentration of Cyclopenthiazide can be increased when it is combined with Mazaticol.Experimental
ME-609ME-609 may increase the hypokalemic activities of Cyclopenthiazide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Cyclopenthiazide.Approved
Mefenamic acidThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Cyclopenthiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Cyclopenthiazide.Experimental
MesalazineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Cyclopenthiazide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclopenthiazide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Cyclopenthiazide.Approved, Illicit
MethanthelineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Methantheline.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Cyclopenthiazide.Approved
MethoserpidineCyclopenthiazide may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of Cyclopenthiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Cyclopenthiazide.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Cyclopenthiazide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Cyclopenthiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Cyclopenthiazide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Metildigoxin.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Cyclopenthiazide.Approved
MetixeneThe serum concentration of Cyclopenthiazide can be increased when it is combined with Metixene.Approved
MetolazoneMetolazone may increase the hypotensive activities of Cyclopenthiazide.Approved
MetoprololMetoprolol may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
MetyrosineCyclopenthiazide may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Cyclopenthiazide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Cyclopenthiazide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Cyclopenthiazide.Approved
MinaprineMinaprine may increase the hypotensive activities of Cyclopenthiazide.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Cyclopenthiazide.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Cyclopenthiazide.Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
MizoribineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Cyclopenthiazide.Approved
MoexiprilMoexipril may increase the hypotensive activities of Cyclopenthiazide.Approved
MofebutazoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Cyclopenthiazide.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclopenthiazide.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Cyclopenthiazide.Approved
MuzolimineCyclopenthiazide may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Cyclopenthiazide.Approved
NafamostatThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Naftifine.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Cyclopenthiazide.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclopenthiazide.Approved
NaproxenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Cyclopenthiazide.Investigational
NebivololNebivolol may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Cyclopenthiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Cyclopenthiazide.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Cyclopenthiazide.Experimental
NicorandilNicorandil may increase the hypotensive activities of Cyclopenthiazide.Approved
NifenazoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Cyclopenthiazide.Approved
NimesulideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Cyclopenthiazide.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Cyclopenthiazide.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Cyclopenthiazide.Approved
NitroaspirinThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Cyclopenthiazide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Cyclopenthiazide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Cyclopenthiazide.Approved, Illicit
ObinutuzumabCyclopenthiazide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
OleandrinThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Oleandrin.Experimental
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Cyclopenthiazide.Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Cyclopenthiazide.Approved
OlopatadineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Cyclopenthiazide.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Cyclopenthiazide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Cyclopenthiazide.Approved
OrgoteinThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Orphenadrine.Approved
OtiloniumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Otilonium.Experimental
OuabainThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Oxitropium.Investigational
OxprenololOxprenolol may increase the hypotensive activities of Cyclopenthiazide.Approved
OxybutyninThe serum concentration of Cyclopenthiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclopenthiazide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cyclopenthiazide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Oxyphenonium.Approved
PancuroniumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Pancuronium.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Cyclopenthiazide.Approved
ParecoxibThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Cyclopenthiazide.Approved
ParicalcitolCyclopenthiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Cyclopenthiazide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Parthenolide.Investigational
PenbutololPenbutolol may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclopenthiazide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Cyclopenthiazide.Approved, Vet Approved
PentoliniumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Cyclopenthiazide.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclopenthiazide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Cyclopenthiazide.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Cyclopenthiazide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Cyclopenthiazide.Approved, Withdrawn
PhenglutarimideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Phenglutarimide.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Cyclopenthiazide.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Cyclopenthiazide.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Cyclopenthiazide.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Cyclopenthiazide.Approved
PhenylbutazoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Cyclopenthiazide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
PindololPindolol may increase the hypotensive activities of Cyclopenthiazide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
PipecuroniumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Cyclopenthiazide.Approved
PirenzepineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Cyclopenthiazide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Cyclopenthiazide.Approved
PiroxicamThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
PolythiazidePolythiazide may increase the hypotensive activities of Cyclopenthiazide.Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Pranoprofen.Experimental
PrasteronePrasterone may increase the hypokalemic activities of Cyclopenthiazide.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Cyclopenthiazide.Investigational
PrazosinPrazosin may increase the hypotensive activities of Cyclopenthiazide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Cyclopenthiazide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Cyclopenthiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Cyclopenthiazide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
PrimidonePrimidone may increase the orthostatic hypotensive activities of Cyclopenthiazide.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Cyclopenthiazide.Approved
ProcyclidineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Propacetamol.Approved
PropanthelineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Propiverine.Investigational
PropranololPropranolol may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Proscillaridin.Experimental
PTC299The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with PTC299.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
QuinidineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Cyclopenthiazide.Approved
RamiprilRamipril may increase the hypotensive activities of Cyclopenthiazide.Approved
RasagilineRasagiline may increase the hypotensive activities of Cyclopenthiazide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclopenthiazide.Approved
RemikirenRemikiren may increase the hypotensive activities of Cyclopenthiazide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
RescinnamineCyclopenthiazide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Cyclopenthiazide.Approved
ResveratrolThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Resveratrol.Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Cyclopenthiazide.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Cyclopenthiazide.Approved
RiociguatCyclopenthiazide may increase the hypotensive activities of Riociguat.Approved
RitodrineRitodrine may increase the hypokalemic activities of Cyclopenthiazide.Approved
RituximabCyclopenthiazide may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Cyclopenthiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Cyclopenthiazide.Approved
SalsalateThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Salsalate.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Cyclopenthiazide.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Cyclopenthiazide.Approved
ScopolamineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Cyclopenthiazide.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Cyclopenthiazide.Approved
SemapimodThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Serrapeptase.Investigational
SertralineSertraline may increase the hyponatremic activities of Cyclopenthiazide.Approved
SildenafilSildenafil may increase the antihypertensive activities of Cyclopenthiazide.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
SitaxentanCyclopenthiazide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphateCyclopenthiazide may increase the nephrotoxic activities of Sodium phosphate.Approved
SolifenacinThe serum concentration of Cyclopenthiazide can be increased when it is combined with Solifenacin.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Cyclopenthiazide.Investigational
SpiraprilSpirapril may increase the hypotensive activities of Cyclopenthiazide.Approved
SRT501The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with SRT501.Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclopenthiazide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Cyclopenthiazide.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Cyclopenthiazide.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Cyclopenthiazide.Approved
TarenflurbilThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Cyclopenthiazide.Experimental, Investigational
TenidapThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Cyclopenthiazide.Approved
TeriflunomideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Teriflunomide.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
TetrahydropalmatineTetrahydropalmatine may increase the hypotensive activities of Cyclopenthiazide.Investigational
TheodrenalineTheodrenaline may increase the hypotensive activities of Cyclopenthiazide.Investigational
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Cyclopenthiazide.Approved, Vet Approved
ThiopentalThiopental may increase the orthostatic hypotensive activities of Cyclopenthiazide.Approved, Vet Approved
Tiaprofenic acidThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneTibolone may increase the hypotensive activities of Cyclopenthiazide.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Cyclopenthiazide.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Cyclopenthiazide.Experimental
TimololTimolol may increase the hypotensive activities of Cyclopenthiazide.Approved
TinoridineThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Cyclopenthiazide.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Cyclopenthiazide.Approved
TolazolineTolazoline may increase the hypotensive activities of Cyclopenthiazide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Cyclopenthiazide.Approved
Tolfenamic AcidThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tolmetin.Approved
TolonidineCyclopenthiazide may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Cyclopenthiazide.Approved
TolterodineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateCyclopenthiazide may increase the hypokalemic activities of Topiramate.Approved
TorasemideTorasemide may increase the hypotensive activities of Cyclopenthiazide.Approved
ToremifeneCyclopenthiazide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyclopenthiazide.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Cyclopenthiazide.Approved
TranilastThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cyclopenthiazide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Cyclopenthiazide.Approved
TravoprostTravoprost may increase the hypotensive activities of Cyclopenthiazide.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Cyclopenthiazide.Approved, Vet Approved
TribenosideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Cyclopenthiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Cyclopenthiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Cyclopenthiazide.Experimental
TrimethaphanThe serum concentration of Cyclopenthiazide can be increased when it is combined with Trimethaphan.Approved
TriptolideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Cyclopenthiazide.Withdrawn
TropatepineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Cyclopenthiazide can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Cyclopenthiazide.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Cyclopenthiazide.Approved
UrapidilUrapidil may increase the hypotensive activities of Cyclopenthiazide.Investigational
ValdecoxibThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Cyclopenthiazide.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Cyclopenthiazide.Approved
VecuroniumThe serum concentration of Cyclopenthiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Cyclopenthiazide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Cyclopenthiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
VincamineVincamine may increase the hypotensive activities of Cyclopenthiazide.Experimental
VinpocetineVinpocetine may increase the hypotensive activities of Cyclopenthiazide.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Cyclopenthiazide.Approved, Investigational
XipamideCyclopenthiazide may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Cyclopenthiazide.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Cyclopenthiazide.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Cyclopenthiazide.Withdrawn
ZofenoprilZofenopril may increase the hypotensive activities of Cyclopenthiazide.Experimental
ZomepiracThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
  1. Johnston GD, Wilson R, McDermott BJ, McVeigh GE, Duffin D, Logan J: Low-dose cyclopenthiazide in the treatment of hypertension: a one-year community-based study. Q J Med. 1991 Feb;78(286):135-43. [PubMed:2031076 ]
  2. Passmore AP, Whitehead EM, Crawford V, McVeigh GE, Johnston GD: The antihypertensive and metabolic effects of low and conventional dose cyclopenthiazide in type II diabetics with hypertension. Q J Med. 1991 Nov;81(295):919-28. [PubMed:1808632 ]
  3. 37. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 455). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8 ]
External Links
ChemSpider
2801
ChEBI
91686
ChEMBL
CHEMBL1373254
ATC Codes
C03AB07 — Cyclopenthiazide and potassiumC03AA07 — CyclopenthiazideC03EA07 — Cyclopenthiazide and potassium-sparing agents
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.279 mg/mLALOGPS
logP1.88ALOGPS
logP1.45ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)9.07ChemAxon
pKa (Strongest Basic)-2.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity88.97 m3·mol-1ChemAxon
Polarizability36.83 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2,4-benzothiadiazine-1,1-dioxides. These are aromatic heterocyclic compounds containing a 1,2,4-benzothiadiazine ring system with two S=O bonds at the 1-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiadiazines
Sub Class
Benzothiadiazines
Direct Parent
1,2,4-benzothiadiazine-1,1-dioxides
Alternative Parents
Secondary alkylarylamines / Organosulfonamides / Benzenoids / Aryl chlorides / Aminosulfonyl compounds / Azacyclic compounds / Organopnictogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives
Substituents
1,2,4-benzothiadiazine-1,1-dioxide / Secondary aliphatic/aromatic amine / Aryl chloride / Aryl halide / Benzenoid / Organosulfonic acid amide / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Aminosulfonyl compound / Sulfonyl
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:43 / Updated on September 16, 2017 00:46